ZBIO — Zenas BioPharma, Inc. Common Stock

Zenas BioPharma, Inc. Common Stock (ZBIO) is a biotechnology company listed on NASDAQ. It is led by Leon Oliver Moulder Jr., M.B.A., based in 852 Winter Street, Waltham, MA, United States, 02451, with about 130 employees. Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Latest reported ZBIO revenue for 2025-09-30 was $0. Net income was -$51.5M. ZBIO currently screens at market cap $798.0M.

Use this ZBIO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ZBIO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ZBIO SEC filings page. Lician reads the product cache first so this HTML stays unique to Zenas BioPharma, Inc. Common Stock even when a live quote feed is slow.